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Abstract: This study analyzed 57 Aspergillus section Fumigati (AF) isolates collected by active and 
passive sampling (N = 450) in several health care facilities and from biological sampling of health 
care workers (N = 25) and controls (N = 22) in Portugal. All isolates were cultured in different me-
dia and screened for azole resistance. Cytotoxicity was assessed for 40 isolates in lung epithelial 
cells and kidney cells using the MTT assay. Aspergillus section Fumigati was prevalent in the health 
care facilities and in nasal swabs from health care workers and controls. All AF isolates reduced 
cell viability and presented medium to high cytotoxicity, with cytotoxicity being significantly 
higher in A549 lung epithelial cells. The cytotoxicity of isolates from air and nasal swab samples 
suggested the inhalation route as a risk factor. Notably, 42% of AF isolates exhibited a pattern of 
reduced susceptibility to some of the most used antifungals available for the treatment of patients 
infected with these fungi. In sum, the epidemiology and clinical relevance of Aspergillus section 
Fumigati should continue to be addressed. A deeper understanding of the mechanisms underlying 
Aspergillus-mediated cytotoxicity is necessary. 
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1. Introduction 
Aspergillus section Fumigati is associated with a high mortality rate in at risk pa-
tients, such as those with asthma, cystic fibrosis, and chronic obstructive lung disease or 
with immune suppression, mostly due to invasive pulmonary aspergillosis—a fatal dis-
ease [1]. It is predictable that over 30 million patients are at risk of developing invasive 
aspergillosis worldwide, mainly due to the use of immunosuppressive therapies [2]. 
Healthcare-associated aspergillosis is most often acquired by inhalation of airborne 
spores causing pulmonary aspergillosis, which the fungus can disseminate in the blood-
stream and reach other organs [3]. Airway colonization by Aspergillus spp. Has also been 
observed in approximately half of patients in an adult pneumology ward with no 
symptoms of aspergillosis [4]. Exposure to Aspergillus section Fumigati can be, therefore, 
considered a risk for both patients and health staff in health care environments (HCE) [5].  
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The genus Aspergillus is classified into four subgenera (Aspergillus, Circumdati, Fu-
migati, and Nidulantes) and 20 sections, each including a number of related species [6,7]. 
The most prevalent in HCE, as in other environments, are Aspergillus sections Fumigati, 
Flavi, Nigri, and Nidulantes [8,9]. Section Fumigati is the most frequently isolated section 
both from respiratory samples from patients and from HCE sampling [10]. Section Fu-
migati is one of the most species-rich sections in the Aspergillus genus, comprising about 
50 to 60 potentially pathogenic species for humans [11]. It is the Aspergillus section that 
has the most reported clinical relevance and is more often associated with respiratory 
symptoms (mainly A. fumigatus sensu stricto).  
The adverse effects resulting from exposure to airborne toxigenic fungi are well 
known. Long-term exposure to toxigenic fungi interferes with natural killer cell activity, 
and may cause symptoms such as cough, fever, headache, anxiety, or depression [12]. 
The induction of immunosuppression and inflammation by exposure to fungi and bio-
aerosols is also described [13,14]. An additional concern regarding A. fumigatus sensu 
stricto is the emergence of acquired azole-resistance in clinical practice and in the envi-
ronment [10,15–19].  
Aspergillus section Fumigati’s clinical relevance has been related to the small size of 
conidia and other virulence factors [9,20,21]. The cytotoxicity effect of Aspergillus section 
Fumigati toxins, such as gliotoxin, has been described [22–24]. While a more recent study 
described cytotoxic and apoptotic effects of Aspergillus section Fumigati conidia in lung 
epithelial cells and fibroblasts [25].  
In the present study, to evaluate the cytotoxicity of Aspergillus section Fumigati from 
ten primary health care centers and one central hospital, isolates were obtained by air, 
passive sampling and workers’ nasal swabbing and were co-cultured with lung epithelial 
cells and kidney cells. An MTT assay was used to determine IC50 levels, and correla-
tional statistical analysis was performed to explore relations between isolates growth in 
different media, including azoles, sampling, and the cytotoxicity effect. 
2. Materials and Methods 
2.1. Health Care Facilities and Sampling Campaign 
Ten Primary Health Care Centres (PHCC) and one Central Hospital (CH) were as-
sessed in Lisbon and Oporto, respectively, from June to July 2018, as part of a wider 
study aiming to propose new procedures to determine exposure to bioburden at HCE 
[26]. The project protocol was first approved by scientific councils from HCE (ref: 
064/CES/INV/2017) and by the Ethical Committee of Escola Superior de Tecnologia da 
Saúde de Lisboa (ref: CE-ESTeSL-No 45-2018). The protocol was in accordance with the 
World Medical Association Declaration of Helsinki and the Oviedo Convention, and in 
agreement with the Portuguese law no 58/2019 of 8 August, regarding data protection 
[26]. A prior evaluation by a certified exposure assessor was developed on site at each 
HCE to identify critical control points in workplaces which could involve higher expo-
sure to microbial contamination. A comprehensive sampling campaign was then held, 
using active and passive sampling methods in both indoor environments (PHCC and 
CH) [27,28]. Active sampling comprised air sampling by impaction (N = 201). Air sam-
pling by impinger was also performed (N = 56) for molecular detection purposes (not 
presented). Passive sampling included surface swabs (N = 126), electrostatic dust cloths 
(EDC, N = 96), settled dust (N = 15), and filters from HVAC system (N = 12) (Table 1). 
Table 1. Samples collected in the HCE analyzed by culture-based methods (Adopted from [27,28]). 
 Air Impaction Surface Swabs EDC Settled Dust HVAC Filters 
PHCC 81 81 81 10 12 
CH 120 45 15 5 0 
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2.2. Volunteers Enrolment and Biological Sampling 
Nasal swabs were collected from volunteer health care workers in the ten PHCC (N 
= 25) and in the CH (N = 22). A control group of 25 healthy volunteers with no occupa-
tional contact with health care facilities was also evaluated in Lisbon. All volunteers 
signed informed consent prior to enrollment in the study. All inherent ethical principles 
were duly observed. Biological samples were obtained through a nasopharyngeal swab 
procedure using transport swabs with Stuart media when necessary. For nasal sampling, 
a swab was inserted about one centimeter into the nostril and rubbed in a circular way. 
The same swab was then used to sample the other nostril following the same procedure. 
For the samples collection, transport swabs with Stuart media were used that were im-
mediately transported to the laboratory after being used. 
2.3. Fungal Culture and Screening of Azole Resistance 
Malt extract agar (MEA) supplemented with chloramphenicol (0.05%), and di-
chloran-glycerol agar (DG18) were used to increase selectivity for fungal growth. 
Sabouraud dextrose agar (SDA) and SDA supplemented with 4 mg/L itraconazole (ITR), 
1 mg/L voriconazole (VOR) or 0.5 mg/L posaconazole (POS) were used for screening of 
azole resistance (adapted from EUCAST 2018) and following the procedures already re-
ported [5,18,19]. The reference strain A. fumigatus ATCC 204,305 was used as a negative 
control and a pan-azole-resistant strain was used as a positive control (both kindly pro-
vided by Reference Unit for Parasitic and Fungal Infections, Department of Infectious 
Diseases of the National Institute of Health, from Dr. Ricardo Jorge). 
After incubation at 27 °C for 5 to 7 days (MEA and DG18) and 27 °C for 4 days (SDA, 
ITR, VOR, and POS), fungal burden densities found in environmental samples (colo-
ny-forming units, CFU/m2) were calculated as previously described [18,27,28]. Fungal 
species were identified microscopically using tease mount or Scotch tape mount and 
lactophenol cotton blue mount procedures. Morphological identification was achieved 
through macro and microscopic characteristics as noted by De Hoog [29]. 
2.4. Aspergillus Section Fumigati Isolation 
After identifying the Fumigati section in any of the media used, an isolate was ob-
tained from each sample in MEA, and the one with the highest possibility of obtaining a 
pure culture of the Fumigati isolate was selected. Aspergillus section Fumigati isolates in 
MEA were retested in azole supplemented media. Before the cytotoxicity assay, Asper-
gillus section Fumigati was inoculated on the yeast extract glucose chloramphenicol 
(YGC) medium in order to revive the colony. Of note, some Fumigati isolates were unable 
to grow at this stage and could not be further analyzed. Then the isolates were inoculated 
on the Czapek’s agar (CZA) medium (final pH = 6.0 ± 0.2, at 25 °C) and grown for 10 days 
at 25 °C and 10 days at 6 °C. The composition of the CZA medium was as follows: su-
crose-30.00 g/L, sodium nitrate-3.00 g/L, dipotassium phosphate-1.00 g/L, potassium 
chloride-0.50 g/L, magnesium sulphate-0.50 g/L, ferrous sulphate-0.01 g/l, Agar-15.00 
g/L. 
2.5. Cell Culture 
Human A549 lung epithelial cells and swine kidney (SK) cells were maintained in 
Eagle’s minimum essential medium (MEM) supplemented with 10,000 units of penicillin 
and 10 mg of streptomycin per mL in 0.9% NaCl (Sigma-Aldrich, Portugal)) and fetal 
bovine serum (Sigma-Aldrich, USA). Cells were detached from the bottom of the culture 
vessel with 0.25% (w/v) Trypsin 0.53 mM EDTA, suspended in the culture medium, and 
the number of cells was counted using Scepter™ 2.0 cell counter (Merck). 
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2.6. Cytotoxicity Evaluation by the MTT Assay 
The cytotoxicity effect was measured by reduction of MTT tetrazolium salt to 
formazan at 510 nm (Hanelt et al. 1994) in A549 and SK cells, using several dilutions of 
Aspergillus section Fumigati isolates. Fumigati isolates were exposed to thermal shock by 
being placed in the temperature of 4 °C for 96 h. From the strains of molds grown in the 
Petri dishes (Czapek-Dox medium) extracts were prepared to be evaporated later to 
dryness under a stream of nitrogen. The extracts contained the equivalent of Aspergillus 
section Fumigati from one Petri dish (62.5 cm2). Next, a series of test dilutions was pre-
pared. The first dilution on assay plate was 31.25 cm2/mL. After the cell count, A549 and 
SK cells were transferred (100 µL) to a 96-well plate (densities of 2.5 × 105 cells/mL) and 
exposed to the several dilutions of Aspergillus section Fumigati isolates for 48 h at 5% CO2, 
37 °C, and humid atmosphere. The lowest concentration of the isolates causing a drop in 
absorption to <50% of cell division activity (IC50) was considered the threshold toxicity 
level. 
2.7. Statistical Analysis 
Data were analyzed using SPSS V26.0 statistical software for windows. The results 
were considered significant at the 5% significance level. To characterize the sample, fre-
quency analysis (n, %) was used for qualitative data and graphical representations ap-
propriate to the nature of the data. To test the normality of the data, the Shapiro-Wilk test 
was used. To study the association between the growth of azoles (no/yes in ITR, VOR, 
and POS) and the medium (MEA, DG18, and SAB) the Chi-Square test by Monte Carlo 
simulation was used, since the assumptions of applicability of the Chi-Square test were 
not verified. To compare the cytotoxicity of IC50 cells (SK and A549) between the MEA 
and DG18 media (once in the SDA media there were only three observations) and be-
tween the growth of azoles (no/yes in ITR, VOR, and POS) the Mann–Whitney test was 
used. To compare the cytotoxicity of IC50 cells (SK and A459) between the type of envi-
ronmental samples (air impaction, nasal swabs (PHCC), and nasal swabs (Control)—the 
others were not considered in the analysis, due to the small number of observations), a 
Kruskal-Wallis test was used. 
3. Results 
3.1. Aspergillus Section Fumigati Isolates 
A total of 57 Aspergillus section Fumigati isolates were recovered from 450 environ-
mental active and passive samples and 47 samples obtained by nasal swabbing. Asper-
gillus section Fumigati isolates were recovered with higher prevalence from DG18 (56.1%) 
and the samples obtained by air impaction, were the environmental samples where it 
was observed more frequently (8.1%) (Table 2). 
















N 6 1 1 1 1 1 6 17 
% of total 10.5% 1.8% 1.8% 1.8% 1.8% 1.8% 10.5% 38.6% 
DG18 
N 16 0 0 1 0 8 16 41 
% of total 28.1% 0.0% 0.0% 1.8% 0.0% 14.0% 28.1% 56.1% 
SDA 
N 0 1 0 1 1 0 0 3 
% of total 0.0% 1.8% 0.0% 1.8% 1.8% 0.0% 0.0% 5.3% 
Aspergillus section Fumigati was identified in all but one type of environmental 
sample (HVAC filters) in the PHCC studied. In the air impaction samples, this section 
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was identified in both MEA and DG18, where it represented 0.13% and 0.41% of the total 
fungal burden, respectively. In all other types of environmental samples, Aspergillus sec-
tion Fumigati was only detected in MEA, representing 0.01% of the total fungal burden in 
the EDCs, 1% in the surface swabs, and 0.94% in the settled dust samples. In the Central 
Hospital (CH), Aspergillus sp. was only identified in air impaction and settled dust sam-
ples. In the air impaction samples, Aspergillus section Fumigati was the most common 
section both in MEA (1.05%) and in DG18 (7.35%). The same trend was found on settled 
dust, where Aspergillus section Fumigati was the most common (20% of the total) (Figure 
1). 
 
Figure 1. Aspergillus sp. and Aspergillus section Fumigati distribution in the PHCC samples (a) and 
CH samples (b) (Adapted from [5,27,28]). 
3.2. Aspergillus Section Fumigati Cytotoxicity Effect 
The cytotoxicity evaluation was obtained from 40 out of the 57 Aspergillus section 
Fumigati isolates, using the MTT assay. The lowest concentration of the isolates causing a 
drop in absorption to <50% of cell division activity was considered the threshold toxicity 
level. The overview of the results is shown in Table 3. The IC50 ranged from 0.7625 
mm2/mL to 0.122 cm2/mL in A549 cells, and from 3.050 mm2/mL to 3.906 cm2/mL in SK 
cells. 
Table 3. Distribution of threshold toxicity level (IC50) of Aspergillus section Fumigati isolates. 
Dilution Step IC50 
A549 SK 
N N 
13 0.7625 mm2/ml 4 0 
12 1.525 mm2/ml 9 0 
11 3.050 mm2/ml 10 6 
10 0.061 cm2/ml 14 10 
9 0.122 cm2/ml 3 14 
8 0.244 cm2/ml 0 3 
7 0.488 cm2/ml 0 5 
6 0.977 cm2/ml 0 1 
4 3.906 cm2/ml 0 1 
N, number of Aspergillus section Fumigati isolates toxic for A549 or SK cells. 
A semi-quantitative scale for cytotoxicity grading was used (adapted from [30]): 
medium cytotoxic effect for IC50 values ranging from 3.906 cm2/mL to 0.977 cm2/mL; 
high cytotoxic effect for IC50 values ranging from 0.488 cm2/mL to 0.7625 mm2/mL. The 
results are depicted in Table 4. Cytotoxicity was confirmed in all Aspergillus section Fu-
migati isolates, with high cytotoxicity observed in 100% of cases in A549 lung epithelial 
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cells, and in 95% of cases in SK cells. Similar results were obtained with isolates from 
nasal swabbing of workers and controls. 
Table 4. Level of cytotoxicity of the Aspergillus section Fumigati isolates. 
Aspergillus Section Fumigati  
Isolates per Sampling 
Isolates with Level of Toxicity n (%) 
Medium High 
A549 SK A549 SK 
Air impaction (N = 13)  0 0 13 (100) 13 (100) 
EDC (N = 1)  0 0 1 (100) 1 (100) 
Settled dust (N = 3)  0 1 (33.3) 3 (100) 2 (66.7) 
Surface swabs (N = 1)  0 0 1 (100) 1 (100) 
Vacuum bag (N = 2)  0 0 2 (100) 2 (100) 
Nasal swab (control) (N = 11)  0 1 (9.1) 11 (100) 10 (90.9) 
Nasal swab (PHCC) (N = 9)  0 0 9 (100) 9 (100) 
Of note, 17 Aspergillus section Fumigati isolates (88.2% from environmental sam-
pling) were able to grow in at least one azole (4 mg/L ITR), including 7 isolates from en-
vironmental samples (mostly air impaction) that were able to grow in two different az-
oles (4 mg/L ITR, and 1 mg/L VOR), of which 4 were able to grow in the three tested az-
oles (4 mg/L ITR, 1 mg/L VOR, and 0.5 mg/L POS) [5,19,27,28]. Regarding nasal samples, 
two Aspergillus section Fumigati isolates were able to grow in 4 mg/L ITR, one of which 
was from PHCC staff, and the other from controls. 
3.3. Correlation and Comparison Analysis 
No significant correlation of IC50 levels was detected between SK and A549 cells (rS 
= 0.212, p = 0.209). Statistically significant differences in IC50 levels were detected be-
tween SK and A549 cells (z = −4.982, p < 0.001), with IC50 being significantly lower in 
A549 cells. The Wilcoxon test also revealed statistically significant differences of IC50 
levels among the two cell types in different media (z = −3.413, p = 0.001 and z = −3.834, p < 
0.001, in MEA and in DG18, respectively), with IC50 levels being significantly lower for 
both media in A549 cells (Table 5). Between MEA and DG18, no statistically significant 
differences in IC50 levels were detected in SK or A549 cells (U = 158, p = 0.705, and U = 
156, p = 0.658, respectively) (Table 6). These results suggest a higher cytotoxicity effect in 
A549 cells, with no influence of the culture media used. 
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Table 5. Comparison of IC50 levels between SK and A549 cells from isolates first isolated on MEA and DG18. Wilcoxon 
test results. 
   Ranks Test Statistics 
   N Mean rank Sum of ranks z p 
Global A549-SK 
Negative ranks 35 a 18.56 649.50 
−4.982 d 0.000 * 
Positive ranks 1 b 16.50 16.50 
Ties 4 c   
Total 40   
MEA media A549-SK 
Negative ranks 15 a 8.00 120.00 
−3.413 d 0.001 * 
Positive ranks 0 b 0.00 0.00 
Ties 2 c   
Total 17   
DG18 media A549-SK 
Negative ranks 19 a 10.00 190.00 
−3.834 d 0.000 * 
Positive ranks 0 b 0.00 0.00 
Ties 1 c   
Total 20   
a. A549 < SK. b. A549 > SK. c. A549 = SK. d. Based on positive ranks. * Statistically significant differences at the 5% signifi-
cance level. 
Table 6. Comparison of IC50 levels in either SK or A549 cells from isolates first isolated on MEA and DG18. Mann–
Whitney test results. 
IC50 Media 
Ranks Test Statistics 
n Mean rank Sum of ranks Mann–Whitney U p 
SK 
MEA 17 19.71 335.00 
158.000 0.705 DG18 20 18.40 368.00 
Total 37   
A549 
MEA 17 19.82 337.00 
156.000 0.658 DG18 20 18.30 366.00 
Total 37   
The Chi-Square test detected one significant association (p = 0.035, 95% C.I. = (0.031, 
0.039)) between nongrowth in ITR and growth in MEA and DG18, with Aspergillus sec-
tion Fumigati presenting a greater predisposition to nongrowth in ITR (Table 7). These 
results indicate that the three media analyzed (MEA, DG18, and SDA) present a signifi-
cant variability with respect to fungal growth in ITR. 
Table 7. Relation between Aspergillus section Fumigati isolates on azole-supplemented SDA (ITR, VOR, and POS) and first 
isolation media (MEA, DG18, and SDA). Results of the Chi-Square test by Monte Carlo simulation. 
 
Growth in Azole Supplemented 
Media 
Chi-Square Test by Monte Carlo Simulation 
ITR 
Total p 
95% Confidence Interval 
No Yes Lower Bound Upper Bound 
Media 
MEA 
n 12 10 22 
0.035 a,* 0.031 0.039 
% 54.5% 45.5% 100.0% 
DG18 
n 23 9 32 
% 71.9% 28.1% 100,0% 
SDA 
n 0 3 3 
% 0.0% 100.0% 100.0% 
Total 
n 35 22 57 
   
% 61.4% 38.6% 100.0% 
VOR 





n 17 5 22 
0.119 a 0.112 0.125 
% 77.3% 22.7% 100.0% 
DG18 
n 30 2 32 
% 93.8% 6.3% 100.0% 
SDA 
n 2 1 3 
% 66.7% 33.3% 100.0% 
Total 
n 49 8 57 
   




n 19 3 22 
0.725 a 0.716 0.734 
% 86.4% 13.6% 100.0% 
DG18 
n 30 2 32 
% 93.8% 6.3% 100.0% 
SDA 
n 3 0 3 
% 100.0% 0.0% 100.0% 
Total 
n 52 5 57 
   
% 91.2% 8.8% 100.0% 
a Based on 10,000 sampled tables with starting seed 2,000,000. * Significant association at the 5% significance level. 
Comparing the cytotoxicity effect (IC50 levels in SK and A459 cells) with Aspergillus 
section Fumigati growth (No/Yes) on azole-supplemented media, no statistically signifi-
cant differences were detected in any of the media (p > 0.05) (Table 8). These results 
suggest that cytotoxicity had no relation with Aspergillus section Fumigati’s ability to 
grow on azole-supplemented media. Despite not being significant, it was found that IC50 
was lower (meaning higher cytotoxicity) in both cells when isolates were not able to grow 
in ITR or when they were able to grow in POS. Regarding VOR, IC50 was lower in SK 
cells for isolates grown in VOR, and in A549 cells when there was no growth in VOR 
(Table 8). 
Table 8. Comparison of IC50 levels (SK and A459 cells) between growth on azoles (No/Yes) in ITR, VOR, and POS media. 




Growth in the 
Azoles 






Mann–Whitney U p 
ITR 
SK 





Yes 17 23.68 402.50 
Total 40   
A549 
No 23 30.68 422.50 
146.500 0.164 Yes 17 38.32 397.50 
Total 40   
VOR 
SK 
No 33 20.80 686.50 
105.500 0.713 Yes 7 19.07 133.50 
Total 40   
A549 
No 33 19.98 659.50 
98.500 0.530 Yes 7 22.93 160.50 
Total 40   
POS 
SK 
No 36 21.04 757.50 
52.500 0.364 Yes 4 15.63 62.50 
Total 40   
A549 
No 36 21.10 759.50 
50.500 0.315 Yes 4 15.13 60.50 
Total 40   
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On the basis of the comparison of IC50 levels for individual isolates of the fungi, 
there were no statistically significant differences between IC50 levels of the analyzed 
samples (air impaction, nasal swab (PHCC) and nasal swab (control) for either SK 
(𝜒𝐾−𝑊
2 (2)= 1.454, p = 0.483) or A459 (𝜒𝐾−𝑊
2 (2)  =  0.514, p = 0.773)) cells. Therefore, it was 
not possible to clearly determine which of the compared sample type displays had a 
more cytotoxicity effect than others. 
4. Discussion 
In the present study, we exposed human lung epithelial A549 cells and swine kidney 
(SK) cells to Aspergillus section Fumigati isolates from the HCE and health care workers 
and found that all Aspergillus section Fumigati isolates tested reduced cell viability, pre-
senting a medium to high cytotoxicity effect in culture. Human lung epithelial cells were 
used as a model for exposure by inhalation [31], and swine kidney cells as a model for 
mammal nephrotoxicity [32], considering the reported nephrotoxicity of some Aspergillus 
section Fumigati toxins [24]. 
Furthermore, we performed correlational statistical analysis and detected a higher 
cytotoxic effect in A549 cells, regardless the culture media used. This is particularly con-
cerning regarding the cytotoxicity effect of Aspergillus section Fumigati isolates from air 
impaction samples and from nasal swabs of PHCC workers and controls, suggesting the 
inhalation route as a risk factor, especially for individuals suffering from asthma [33] and 
immunocompromised individuals [9,34,35].  
Indeed, cytotoxic toxins of Aspergillus section Fumigati act on different cells to induce 
cell death. The cytotoxicity and apoptotic effects of gliotoxin, the main secondary me-
tabolite of Aspergillus section Fumigati have been reported in macrophages [22,24]. 
Trypacidin, another toxin from Aspergillus section Fumigati, was also reported to have a 
cytotoxicity effect on lung cells [23]. Other studies using lung epithelial cells to address 
the association between Fumigati conidia and airways colonization revealed contradic-
tory results on the pro-inflammatory effect [36,37]. 
Very few studies focus on the cytotoxicity of fungi from environments occupied by 
humans, namely, in HCE. Most available studies focus on the cytotoxicity of Penicillium 
sp., Aspergillus sp. or Stachybotrys sp. genera, mostly recovered from dwellings with in-
filtrations and humid environments [38–42], from occupational settings [43,44], or even 
from protection devices used in high fungal load settings such as the waste sorting in-
dustry [45–47]. One study evaluating the concentration of airborne fungi in rooms of 
asthma patients concluded that the home environment was a potential source of expo-
sure to molds and a risk factor for asthma patients [33]. A previous study revealed that 
47% of the evaluated airborne fungi, collected from humid apartments in Scotland, dis-
played cytotoxicity in vivo [38]. Other in vitro studies refer to the cytotoxicity of building 
materials as related to their contamination by molds and mycotoxins [48].  
Regarding the cytotoxicity of the Aspergillus genera, a study by Gniadek et al. re-
ported a low cytotoxicity effect of airborne Aspergillus section Flavi recovered from hos-
pital rooms and tracheostomy tubes [49]. A previous study comparing the cytotoxicity of 
indoor molds, by means of the MTT assay, concluded that IC50 for Aspergillus section 
Fumigati spores was higher than for Aspergillus section Nigri spores [40], whereas several 
other studies describe that Aspergillus section Fumigati present the highest cytotoxicity 
among Aspergillus species [39,42], including one study in a hospital environment [50].  
Aspergillus section Fumigati was more prevalent in DG18 (compared to MEA), thus, 
supporting the use of more than one culture media in HCE assessments. Indeed, DG18 
restricts the size of fungal colonies with higher growth rates that often hinder Aspergillus 
sp. [51]. Therefore, a more accurate characterization of the contamination by this Asper-
gillus section should be considered [52].  
The high prevalence of section Fumigati obtained by air impaction also highlights the 
risk of exposure by inhalation of airborne spores [3]. It is known that, when suspended in 
the air, the 2–3 μm conidia of this Aspergillus section can reach deeply inside the respir-
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atory system (alveoli or the sinuses) after inhalation [53]. Previous work on health care 
units evaluated the air quality of indoor hospital environments, namely, in adult and 
new-born intensive care units, as well as surrounding areas such as corridors and hall-
ways, concluding that fungal spores’ contamination was within limits (750 CFU.m−3) ac-
cording to current norms [54]. Other studies, however, refer to fungal contamination in 
hospital room’s frequently exceeding limits [5,27,28,55–57]. In the enlarged project where 
the isolates from this study were recovered, the quantification limit complied with the 
Portuguese legislation in most of the HCE assessed (I/O < 1), which is the cut off to avoid 
fungal species identification. However, a deeper analysis enabled the identification of 
harmful fungal species (including section Fumigati among others), which are indicators 
for corrective measure implementation in the same Portuguese legal framework [27]. 
Besides fungal quantification suggested in most guidelines and legislation, the 
identification of toxigenic fungal species is also important for risk assessment [27,28]. 
Performing regular fungal assessments, targeting for Aspergillus section Fumigati, may 
help to unveil contamination sources at HCE [5,58]. Moreover, the sampling approach 
should comprise both active (air) and passive sampling methods and be adjusted to the 
identified contamination sources, contextual information, and variability of the exposure 
[52].  
The quality guarantee of the HCE is aligned with the Sustainable Development 
Goals (SDGs), to ensure healthy lives and promote well-being for all at all ages (Goal 3) 
[59]. Studies held in European hospitals [60] reported that nosocomial infections signifi-
cantly increase morbidity and mortality rates, with most of these infections being trans-
mitted by airborne pathogens [61]. These specific indoor environments also present a 
high risk of cross infection between staff and patients. Additionally, fungal contamina-
tion in the air and on hospital surfaces has been associated with the number of fungal 
infections in hospitalized immunocompromised patients [9,34]. Monitoring and control 
of microbial contamination in HCE is, therefore, mandatory as it is crucial to prevent and 
control hospital-acquired infections [62,63]. Notably, several Aspergillus section Fumigati 
isolates from the environmental sampling were also able to grow in at least one azole, 
including isolates from air samples able to grow in two or more different azoles. This 
might be particularly critical in the HCE, where patients, visitors, and staff might be ex-
posed, and in particular more susceptible populations, such as immunocompromised 
individuals [10,15,35]. Azole resistance must be confirmed in future studies, through an-
tifungal susceptibility testing, for a more precise characterization of the relation between 
cytotoxicity and azole resistance of Aspergillus section Fumigati isolates collected in the 
environment of healthcare facilities. Unfortunately, the section Fumigati was classified 
based on macroscopic and microscopic characteristics and because of that it was impos-
sible to identify the species among the section. However, in previous studies held by the 
same team also with environmental isolates from different indoor environments, results 
revealed a good correlation between phenotypic and molecular identification [19,64]. 
Further studies should comprehend molecular identification of Aspergillus isolates and 
cytotoxicity analyses. 
5. Conclusions 
In conclusion, Aspergillus section Fumigati was found to be a prevailing species in the 
assessed health care facilities and in nasal swab samples from health care workers. The 
presence of cytotoxic and azole resistant Aspergillus section Fumigati isolates in the HCE 
environment poses an additional risk for patients and health care workers, especially for 
immunocompromised individuals. The epidemiology and clinical relevance of this spe-
cies should continue to be addressed, as a reduced susceptibility to azoles—some of the 
most used antifungals available—may lead to therapeutic failure in the treatment of 
fungal infections such as invasive aspergillosis. More studies on this topic are necessary 
to link Aspergillus section Fumigati cytotoxicity with nosocomial aspergillosis. 
J. Fungi 2021, 7, 839 11 of 13 
 
 
Author Contributions: Conceptualization, C.V., M.T. and L.A.C.; methodology, C.V., M.T. and 
L.A.C.; formal analysis, B.A., M.D., E.R., E.C. and E.S.; investigation, C.V., M.T. and L.A.C.; re-
sources, C.V. and M.T.; writing—original draft preparation, C.V., M.T., B.A., M.D., E.R., E.C., E.S 
and L.A.C.; writing—review and editing, C.V., M.T. and L.A.C.; supervision, C.V., M.T. and L.A.C.; 
project administration, C.V. and M.T.; funding acquisition, C.V. and M.T. All authors have read 
and agreed to the published version of the manuscript. 
Funding: It was co-supported by FCT—Fundação para Ciência e Tecnologia for funding the project 
EXPOsE—Establishing protocols to assess occupational exposure to microbiota in clinical settings 
(02/SAICT/2016—Project no 23222), by the Instituto Politécnico de Lisboa, Lisbon, Portugal for 
funding the Project “Occupational exposure of ambulance drivers to bioburden” 
(IPL/2020/BIO-AmbuDrivers_ESTeSL) and by the Polish Minister of Science and Higher Education, 
under the program “Regional Initiative of Excellence” in 2019–2022 (Grant No. 008/RID/2018/19). 
Institutional Review Board Statement: The study was conducted according to the guidelines of 
the Declaration of Helsinki, and approved by the Ethics Committee of Escola Superior de Tecno-
logia da Saúde de Lisboa (ref: CE-ESTeSL-No 45-2018).  
Informed Consent Statement: Informed consent was obtained from all subjects involved in the 
study. 
Acknowledgments: H&TRC authors gratefully acknowledge the FCT/MCTES national support 
through the UIDB/05608/2020 and UIDP/05608/2020. 
Conflicts of Interest: The authors declare no conflict of interest. 
References 
1. Denning, D.W. Invasive aspergillosis. Clin. Infect. Dis. 1998, 26, 781–803. 
2. LIFE. Available online: http://www.life-worldwide.org/ (Accessed on 1 of September 2021). 
3. Weber, D.J.; Peppercorn, A.; Miller, M.B.; Sickbert-Benett, E.; Rutala, W.A. Preventing healthcare-associated Aspergillus infec-
tions: Review of recent CDC/HICPAC recommendations. Med. Mycol. 2009, 47, 199–209, doi:10.1080/13693780802709073. 
4. Tashiro, T.; Izumikawa, K.; Tashiro, M.; Takazono, T.; Morinaga, Y.; Yamamoto, K.; Imamura, Y.; Miyazaki, T.; Seki, M.; Ka-
keya, H.; et al. Diagnostic significance of Aspergillus species isolated from respiratory samples in an adult pneumology ward. 
Med. Mycol. 2011, 49, 1–7, doi:10.3109/13693786.2010.548084. 
5. Viegas, C.; Almeida, B.; Gomes, A.Q.; Carolino, E.; Caetano, L.A. Aspergillus spp. prevalence in Primary Health Care Centres: 
Assessment by a novel multi-approach sampling protocol. Environ. Res. 2019, 175, 133–141, doi:10.1016/j.envres.2019.05.015. 
6. Houbraken, J.; de Vries, R.P.; Samson, R.A. Modern Taxonomy of Biotechnologically Important Aspergillus and Penicillium 
Species. Adv. Appl. Microbiol. 2014, 86, 199–249. 
7. Hubka, V.; Nováková, A.; Kolařík, M.; Jurjević, Ž.; Peterson, S.W. Revision of Aspergillus section Flavipedes: Seven new spe-
cies and proposal of section Jani sect. nov. Mycologia 2015, 107, 169–208, doi:10.3852/14-059. 
8. Warris, A.; Voss, A.; Verweij, P.E. Hospital sources of Aspergillus species: New routes of transmission? Rev. Iberoam. Micol. 
2001, 18, 156–162. 
9. Sabino, R. Exposure to Fungi in Health Care Facilities. In Encyclopedia of Mycology; Elsevier: Amsterdam, The Netherlands, 
2021; pp. 1–10. 
10. Verweij, P.E.; Chowdhary, A.; Melchers, W.J.G.; Meis, J.F. Azole resistance in Aspergillus fumigatus: Can we retain the clinical 
use of mold-active antifungal azoles? Clin. Infect. Dis. 2016, 62, 362–368, doi:10.1093/cid/civ885. 
11. Hubka, V.; Dudová, Z.; Kubátová, A.; Frisvad, J.C.; Yaguchi, T.; Horie, Y.; Jurjević, Ž.; Hong, S.-B.; Kolařík, M. Taxonomic 
novelties in Aspergillus section Fumigati: A. tasmanicus sp. nov., induction of sexual state in A. turcosus and overview of re-
lated species. Plant Syst. Evol. 2017, 303, 787–806, doi:10.1007/s00606-017-1400-4. 
12. Anyanwu, E.; Campbell, A.W.; Jones, J.; Ehiri, J.E.; Akpan, A.I. The Neurological Significance of Abnormal Natural Killer Cell 
Activity in Chronic Toxigenic Mold Exposures. Sci. World J. 2003, 3, 1128–1137, doi:10.1100/tsw.2003.98. 
13. Sutton, P.; Newcombe, N.R.; Waring, P.; Müllbacher, A. In vivo immunosuppressive activity of gliotoxin, a metabolite pro-
duced by human pathogenic fungi. Infect. Immun. 1994, 62, 1192–1198, doi:10.1128/iai.62.4.1192-1198.1994. 
14. Cramer, R.A.; Rivera, A.; Hohl, T.M. Immune responses against Aspergillus fumigatus. Curr. Opin. Infect. Dis. 2011, 24, 315–322, 
doi:10.1097/QCO.0b013e328348b159. 
15. Nature Microbiology Stop neglecting fungi. Nat. Microbiol. 2017, 2, 17120, doi:10.1038/nmicrobiol.2017.120. 
16. Jeanvoine, A.; Rocchi, S.; Reboux, G.; Crini, N.; Crini, G.; Millon, L. Azole-resistant Aspergillus fumigatus in sawmills of East-
ern France. J. Appl. Microbiol. 2017, 123, 172–184, doi:10.1111/jam.13488. 
17. Vaezi, A.; Fakhim, H.; Javidnia, J.; Khodavaisy, S.; Abtahian, Z.; Vojoodi, M.; Nourbakhsh, F.; Badali, H. Pesticide behavior in 
paddy fields and development of azole-resistant Aspergillus fumigatus: Should we be concerned? J. Mycol. Med. 2018, 28, 59–64, 
doi:10.1016/j.mycmed.2017.12.007. 
J. Fungi 2021, 7, 839 12 of 13 
 
 
18. Viegas, C.; Almeida, B.; Aranha Caetano, L.; Afanou, A.; Straumfors, A.; Veríssimo, C.; Gonçalves, P.; Sabino, R. Algorithm to 
assess the presence of Aspergillus fumigatus resistant strains: The case of Norwegian sawmills. Int. J. Environ. Health Res. 2020, 
19, 1–9, doi:10.1080/09603123.2020.1810210. 
19. Gonçalves, P.; Melo, A.; Dias, M.; Almeida, B.; Caetano, L.A.; Veríssimo, C.; Viegas, C.; Sabino, R. Azole-Resistant Aspergillus 
fumigatus Harboring the TR34/L98H Mutation: First Report in Portugal in Environmental Samples. Microorganisms 2020, 9, 57, 
doi:10.3390/microorganisms9010057. 
20. Watanabe, A.; Kamei, K.; Sekine, T.; Higurashi, H.; Ochiai, E.; Hashimoto, Y.; Nishimura, K. Cytotoxic Substances from Asper-
gillus fumigatus in Oxygenated or Poorly Oxygenated Environment. Mycopathologia 2004, 158, 1–7, doi:10.1023/B: MY-
CO.0000038439.56108.3c. 
21. Varga, J.; Baranyi, N.; Chandrasekaran, M.; Vágvölgyi, C.; Kocsubé, S. Mycotoxin producers in the Aspergillus genus: An 
update. Acta Biol. Szeged. 2015, 59, 151–167. 
22. Malekinejad, H.; Fani, F.; Shafie-Irannejad, V.; Fink-Gremmel, F. Aspergillus fumigatus toxins cause cytotoxic and apoptotic 
effects on human T lymphocytes (Jurkat cells). World Mycotoxin J. 2013, 6, 65–71, doi:10.3920/WMJ2012.1481. 
23. Gauthier, T.; Wang, X.; Sifuentes Dos Santos, J.; Fysikopoulos, A.; Tadrist, S.; Canlet, C.; Artigot, M.P.; Loiseau, N.; Oswald, 
I.P.; Puel, O. Trypacidin, Spore-Borne Toxin from Aspergillus fumigatus, Is Cytotoxic to Lung Cells. PLoS One 2012, 7, e29906, 
doi: 10.1371/journal.pone.0029906. 
24. Brown, R.; Priest, E.; Naglik, J.R.; Richardson, J.P. Fungal Toxins and Host Immune Responses. Front. Microbiol. 2021, 12, 
doi:10.3389/fmicb.2021.643639. 
25. Kushima, H.; Tsunoda, T.; Matsumoto, T.; Kinoshita, Y.; Izumikawa, K.; Shirasawa, S.; Fujita, M.; Ishii, H. Effects of Aspergillus 
fumigatus Conidia on Apoptosis and Proliferation in an In Vitro Model of the Lung Microenvironment. Microorganisms 2021, 9, 
1435, doi:10.3390/microorganisms9071435. 
26. Law no 58/2019. Diário da República n.o 151/2019, Série I 2019-08-08; Assembleia da República: Lisbon, Portugal, 2019; pp. 3–40. 
27. Viegas, C.; Almeida, B.; Monteiro, A.; Caetano, L.A.; Carolino, E.; Gomes, A.Q.; Twarużek, M.; Kosicki, R.; Marchand, G.; 
Viegas, S. Bioburden in health care centers: Is the compliance with Portuguese legislation enough to prevent and control in-
fection? Build. Environ. 2019, 160, 106226, doi:10.1016/j.buildenv.2019.106226. 
28. Viegas, C.; Almeida, B.; Monteiro, A.; Paciência, I.; Rufo, J.; Aguiar, L.; Lage, B.; Diogo Gonçalves, L.M.; Caetano, L.A.; Caro-
lino, E.; et al. Exposure assessment in one central hospital: A multi-approach protocol to achieve an accurate risk characteriza-
tion. Environ. Res. 2020, 181, 108947, doi:10.1016/j.envres.2019.108947. 
29. De Hoog, G.S. Atlas of Clinical Fungi, 2nd Edition; Amer Society for Microbiology: Washington, DC, USA, 2000. ISBN 
9789070351434. 
30. Gniadek, A.; Krzyściak, P.; Twarużek, M.; Macura, A. Occurrence of fungi and cytotoxicity of the species: Aspergillus ochraceus, 
Aspergillus niger and Aspergillus flavus isolated from the air of hospital wards. Int. J. Occup. Med. Environ. Health 2017, 30, 
30(2),231-239, doi:10.13075/ijomeh.1896.00841. 
31. Swain, R.J.; Kemp, S.J.; Goldstraw, P.; Tetley, T.D.; Stevens, M.M. Assessment of Cell Line Models of Primary Human Cells by 
Raman Spectral Phenotyping. Biophys. J. 2010, 98, 1703–1711, doi:10.1016/j.bpj.2009.12.4289. 
32. Heussner, A.; Bingle, L. Comparative Ochratoxin Toxicity: A Review of the Available Data. Toxins 2015, 7, 4253–4282, 
doi:10.3390/toxins7104253. 
33. Fairs, A.; Agbetile, J.; Bourne, M.; Hargadon, B.; Monteiro, W.R.; Morley, J.P.; Edwards, R.E.; Wardlaw, A.J.; Pashley, C.H. 
Isolation of Aspergillus fumigatus from sputum is associated with elevated airborne levels in homes of patients with asthma. 
Indoor Air 2013, 23, 275–284, doi:10.1111/ina.12020. 
34. Kanamori, H.; Rutala, W.A.; Sickbert-Bennett, E.E.; Weber, D.J. Review of Fungal Outbreaks and Infection Prevention in 
Healthcare Settings During Construction and Renovation. Clin. Infect. Dis. 2015, 61, 433–444, doi:10.1093/cid/civ297. 
35. Brambilla, A.; Buffoli, M.; Capolongo, S. Measuring hospital qualities. A preliminary investigation on Health Impact Assess-
ment possibilities for evaluating complex buildings. Acta Biomed. 2019, 90, 54. 
36. Berkova, N.; Lair-Fulleringer, S.; Féménia, F.; Huet, D.; Wagner, M.-C.; Gorna, K.; Tournier, F.; Ibrahim-Granet, O.; Guillot, J.; 
Chermette, R.; et al. Aspergillus fumigatus conidia inhibit tumour necrosis factor-or staurosporine-induced apoptosis in epithe-
lial cells. Int. Immunol. 2006, 18, 139–150, doi:10.1093/intimm/dxh356. 
37. Beisswenger, C.; Hess, C.; Bals, R. Aspergillus fumigatus conidia induce interferon-signalling in respiratory epithelial cells. Eur. 
Respir. J. 2012, 39, 411–418, doi:10.1183/09031936.00096110. 
38. Smith, J.E.; Anderson, J.G.; Lewis, C.W.; Murad, Y.M. Cytotoxic fungal spores in the indoor atmosphere of the damp domestic 
environment. FEMS Microbiol. Lett. 1992, 100, 337–343, doi:10.1111/j.1574-6968.1992.tb14061.x. 
39. Kamei, K.; Watanabe, A.; Nishimura, K.; Miyaji, M. Cytotoxicity of Aspergillus fumigatus Culture Filtrate Against Macrophages. 
J-STAGE 2002, 43, 37–41, doi:10.3314/jjmm.43.37. 
40. Schulz, T.; Senkpiel, K.; Ohgke, H. Comparison of the toxicity of reference mycotoxins and spore extracts of common indoor 
moulds. Int. J. Hyg. Environ. Health 2004, 207, 267–277, doi:10.1078/1438-4639-00282. 
41. Huttunen, K.; Rintala, H.; Hirvonen, M.-R.; Vepsäläinen, A.; Hyvärinen, A.; Meklin, T.; Toivola, M.; Nevalainen, A. Indoor air 
particles and bioaerosols before and after renovation of moisture-damaged buildings: The effect on biological activity and 
microbial flora. Environ. Res. 2008, 107, 291–298, doi:10.1016/j.envres.2008.02.008. 
J. Fungi 2021, 7, 839 13 of 13 
 
 
42. Slesiona, S.; Gressler, M.; Mihlan, M.; Zaehle, C.; Schaller, M.; Barz, D.; Hube, B.; Jacobsen, I.D.; Brock, M. Persistence versus 
Escape: Aspergillus terreus and Aspergillus fumigatus Employ Different Strategies during Interactions with Macrophages. PLoS 
One 2012, 7, e31223, doi:10.1371/journal.pone.0031223. 
43. Gutarowska, B.; Skóra, J.; Stępień, L.; Twarużek, M.; Błajet-Kosicka, A.; Otlewska, A.; Grajewski, J. Estimation of fungal con-
tamination and mycotoxin production at workplaces in composting plants, tanneries, archives and libraries. World Mycotoxin J. 
2014, 7, 345–355, doi:10.3920/WMJ2013.1640. 
44. Viegas, S.; Caetano, L.; Korkalainen, M.; Faria, T.; Pacífico, C.; Carolino, E.; Quintal Gomes, A.; Viegas, C. Cytotoxic and In-
flammatory Potential of Air Samples from Occupational Settings with Exposure to Organic Dust. Toxics 2017, 5, 8, 
doi:10.3390/toxics5010008. 
45. Viegas, C.; Twarużek, M.; Dias, M.; Almeida, B.; Carolino, E.; Kosicki, R.; Soszczyńska, E.; Grajewski, J.; Caetano, L.A.; Viegas, 
S. Assessment of the microbial contamination of mechanical protection gloves used on waste sorting industry: A contribution 
for the risk characterization. Environ. Res. 2020, 189, 109881, doi:10.1016/j.envres.2020.109881. 
46. Viegas, C.; Twarużek, M.; Dias, M.; Almeida, B.; Carolino, E.; Soszczyńska, E.; Ałtyn, I.; Viegas, S.; Caetano, L.A. Cytotoxic 
effect of filtering respiratory protective devices from the waste sorting industry: Is in vitro toxicology useful for risk charac-
terization? Environ. Res. 2020, 191, 110134, doi:10.1016/j.envres.2020.110134. 
47. Viegas, C.; Twarużek, M.; Dias, M.; Almeida, B.; Carolino, E.; Soszczyńska, E.; Viegas, S.; Aranha Caetano, L. Cytotoxicity of 
filtering respiratory protective devices from the waste sorting industry: A comparative study between interior layer and ex-
halation valve. Environ. Int. 2021, 155, 106603, doi:10.1016/j.envint.2021.106603. 
48. Gutarowska, B. Hyphate Fungi in Building Materials. Increase and Production of Mycotoxins and Allergens; Lodz University 
of Technology Press: Lodz, Poland, 2010. 
49. Gniadek, A.; Krzyściak, P.; Hawryszuk, A.; Macura, A.B.; Brzostek, T.; Składzień, J. Mycobiota of the air in hospital rooms and 
the fungal colonisation of tracheostomy tubes used by patients diagnosed with larynx cancer-preliminary research. Ann. Para-
sitol. 2013, 59, 67–71. 
50. Gniadek, A.; Macura, A.B.; Górkiewicz, M. Cytotoxicity of Aspergillus fungi isolated from hospital environment. Polish J. Mi-
crobiol. 2011, 60, 59–63. 
51. Viegas, C.; Twarużek, M.; Lourenço, R.; Dias, M.; Almeida, B.; Caetano, L.A.; Carolino, E.; Gomes, A.Q.; Kosicki, R.; 
Soszczyńska, E.; et al. Bioburden Assessment by Passive Methods on a Clinical Pathology Service in One Central Hospital from 
Lisbon: What Can it Tell Us Regarding Patients and Staff Exposure? Atmosphere 2020, 11, 351, doi:10.3390/atmos11040351. 
52. Viegas, C.; Caetano, L.A.; Viegas, S. Occupational exposure to Aspergillus section Fumigati: Tackling the knowledge gap in 
Portugal. Environ. Res. 2021, 194, 110674, doi:10.1016/j.envres.2020.110674. 
53. Dagenais, T.R.T.; Keller, N.P. Pathogenesis of Aspergillus fumigatus in Invasive Aspergillosis. Clin. Microbiol. Rev. 2009, 22, 447–
465, doi:10.1128/CMR.00055-08. 
54. Macedo, J.I.; Kubota, T.H.; Matsumoto, L.S.; Giordani, A.T.; Takayanagui, A.M.M.; Mendes, A.A.; Bertolini, D.A. Air quality in 
a hospital environment. WIT Trans. Built. Environ. 2013, 134, 737–747. 
55. Falvey, D.G.; Streifel, A.J. Ten-year air sample analysis of Aspergillus prevalence in a university hospital. J. Hosp. Infect. 2007, 
67, 35–41, doi:10.1016/j.jhin.2007.06.008. 
56. Krajewska-Kułak, E.; Łukaszuk, C.; Hatzopulu, A.; Bousmoukilia, S.; Terovitou, C.; Amanatidou, A.; Danilidis, D. Indoor air 
studies of fungi contamination at the Department of Pulmonology and Internal Medicine in Kavala Hospital in Greece. Adv. 
Med. Sci. 2009, 54, doi:10.2478/v10039-009-0048-x. 
57. Kim, K.Y.; Kim, Y.S.; Kim, D. Distribution Characteristics of Airborne Bacteria and Fungi in the General Hospitals of Korea. 
Ind. Health 2010, 48, 236–243, doi:10.2486/indhealth.48.236. 
58. Ruiz-Camps, I.; Aguado, J.M.; Almirante, B.; Bouza, E.; Ferrer-Barbera, C.F.; Len, O.; Lopez-Cerero, L.; Rodríguez-Tudela, J.L.; 
Ruiz, M.; Solé, A.; et al. Guidelines for the prevention of invasive mould diseases caused by filamentous fungi by the Spanish 
Society of Infectious Diseases and Clinical Microbiology (SEIMC). Clin. Microbiol. Infect. 2011, 17, 1–24, 
doi:10.1111/j.1469-0691.2011.03477.x. 
59. United Nations, Department of Economic and Social Affairs. The 17 Goals Sustainable Development. Available online 
https://sdgs.un.org/goals. (Accessed on 1 of September 2021). 
60. Kaoutar, B.; Joly, C.; L’Hériteau, F.; Barbut, F.; Robert, J.; Denis, M.; Espinasse, F.; Merrer, J.; Doit, C.; Costa, Y.; et al. Noso-
comial infections and hospital mortality: A multicentre epidemiological study. J. Hosp. Infect. 2004, 58, 268–275, 
doi:10.1016/j.jhin.2004.06.006. 
61. Kowalski, W. Hospital Airborne Infection Control; CRC Press: Boca Raton, FL, USA, 2011. 
62. Ferdyn-Grygierek, J. Monitoring of indoor air parameters in large museum exhibition halls with and without air-conditioning 
systems. Build. Environ. 2016, 107, 113–126, doi:10.1016/j.buildenv.2016.07.024. 
63. Zahar, J.-R.; Jolivet, S.; Adam, H.; Dananché, C.; Lizon, J.; Alfandari, S.; Boulestreau, H.; Baghdadi, N.; Bay, J.-O.; Bénéteau, 
A.-M.; et al. Quelles mesures pour maîtriser le risque infectieux chez les patients immunodéprimés? Recommandations for-
malisées d’experts. J. Mycol. Med. 2017, 27, 449–456, doi:10.1016/j.mycmed.2017.10.004. 
64. Simões, D.; Aranha Caetano, L.; Veríssimo, C.; Viegas, C.; Sabino, R. Aspergillus collected in specific indoor settings: their 
molecular identification and susceptibility pattern. Int. J. Environ. Health Res. 2021, 31, 248–257, doi: 
10.1080/09603123.2019.1650903. 
 
